Researchers engineer bacteria with potential to help develop vaccines and immunotherapies 

Image | Freepik

In a study published in Nature Chemical Biology, scientists from the University of Delaware have successfully engineered bacteria that can produce an unconventional amino acid, para-nitro-L-phenylalanine (pN-Phe). These findings provide a foundation for developing unique vaccines and immunotherapies in the future.

The focus of this study was para-nitro-L-phenylalanine (pN-Phe), a non-standard amino acid that does not naturally occur among the twenty standard amino acids. pN-Phe has been used by other research groups to help the immune system mount a response to proteins that it does not ordinarily respond to. This attribute holds immense promise for combating diseases caused by irregular proteins that evade the immune system's detection.

"The nitro chemical functional group has valuable properties and has been underexplored by folks who are trying to rewire metabolism," says co-author Aditya Kunjapur. "pN-Phe also has a nice history in the literature – it can be added to a protein from a mouse, delivered back to mice, and the immune system will no longer tolerate the original version of that protein. That ability has promise for the treatment or prevention of diseases that are caused by rogue proteins that the immune system struggles to lock onto."

Genetic code expansion methods allowed the researchers to increase the 'alphabet' of available amino acids encoded by DNA. By coupling metabolic engineering techniques with genetic code expansion, the researchers were able to create a system that produces nitrated proteins autonomously.

"Because of the nitro functional group chemistry, the amino acid that we picked as our target for this project was unconventional, and many scientists within our field may not have expected that it could be made using biosynthesis," says Kunjapur.

The next step for this research is to optimise their methods to synthesise higher amounts of nitrated proteins and expand this work to other microorganisms. The long-term goal is to further refine this platform for applications related to vaccines or immunotherapies, efforts that are supported by Kunjapur’s 2021 AIChE Langer Prize and the 2022 National Institutes of Health Director’s New Innovator Award. To further support this long-term goal, Kunjapur and Neil Butler, a doctoral candidate and first author on this paper, co-founded Nitro Biosciences.

"I think the implications are interesting, in that you can take a bacterium’s central metabolism, its ability to produce different compounds, and with a few modifications you are able to expand its chemical repertoire," said Butler. "The nitro functionality is rare in biology and absent from the standard 20 amino acids, but we showed bacterial metabolism is malleable enough that it can be rewired to create and integrate this functionality."

Kunjapur added: "Bacteria are potentially useful drug delivery vehicles. We think we have created a tool that could leverage the ability of bacteria to produce target antigens within the body and exploit the ability of nitration to shine a light on those antigens at the same time."

This article was originally published at eurekalert.org. The complete report can be read here.